[go: up one dir, main page]

CO2018001290A2 - Proceso para la producción de cannabidiol y delta-9-tetrahidrocannabinol - Google Patents

Proceso para la producción de cannabidiol y delta-9-tetrahidrocannabinol

Info

Publication number
CO2018001290A2
CO2018001290A2 CONC2018/0001290A CO2018001290A CO2018001290A2 CO 2018001290 A2 CO2018001290 A2 CO 2018001290A2 CO 2018001290 A CO2018001290 A CO 2018001290A CO 2018001290 A2 CO2018001290 A2 CO 2018001290A2
Authority
CO
Colombia
Prior art keywords
cannabidiol
compound
derivative
tetrahydrocannabinol
delta
Prior art date
Application number
CONC2018/0001290A
Other languages
English (en)
Inventor
Lukas Dialer
Denis Petrovic
Ulrich Weigl
Original Assignee
Noramco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57730761&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2018001290(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Noramco Inc filed Critical Noramco Inc
Publication of CO2018001290A2 publication Critical patent/CO2018001290A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/11Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/11Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms
    • C07C37/14Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms by addition reactions, i.e. reactions involving at least one carbon-to-carbon unsaturated bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78Ring systems having three or more relevant rings
    • C07D311/80Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

RESUMEN La presente descripción se refiere a la preparación de un compuesto de cannabidiol o un derivado del mismo. El compuesto de cannabidiol o un derivado del mismo se puede preparar por medio de una reacción catalizada con ácido de un di-halo-olivetol seleccionado y sustituido adecuadamente o derivado del mismo con un alqueno cíclico seleccionado y sustituido adecuadamente para producir un compuesto de dihalo-cannabidiol o derivado del mismo. El compuesto de dihalo-cannabidiol o derivado del mismo se puede producir con alto rendimiento, alta estereoespecificidad o ambos. Luego se puede convertir en condiciones reductoras a un compuesto de cannabidiol o derivados del mismo.
CONC2018/0001290A 2015-07-10 2018-02-08 Proceso para la producción de cannabidiol y delta-9-tetrahidrocannabinol CO2018001290A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562191097P 2015-07-10 2015-07-10
US15/199,528 US10059683B2 (en) 2015-07-10 2016-06-30 Process for the production of cannabidiol and delta-9-tetrahydrocannabinol
PCT/US2016/040635 WO2017011210A1 (en) 2015-07-10 2016-07-01 Process for the production of cannabidiol and delta-9-tetrahydrocannabinol

Publications (1)

Publication Number Publication Date
CO2018001290A2 true CO2018001290A2 (es) 2018-04-19

Family

ID=57730761

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0001290A CO2018001290A2 (es) 2015-07-10 2018-02-08 Proceso para la producción de cannabidiol y delta-9-tetrahidrocannabinol

Country Status (21)

Country Link
US (4) US10059683B2 (es)
EP (2) EP3319952B8 (es)
JP (2) JP6810842B2 (es)
CN (1) CN108137526A (es)
AU (2) AU2016294264B2 (es)
BR (1) BR112018000497A2 (es)
CA (1) CA2992043C (es)
CL (2) CL2018000079A1 (es)
CO (1) CO2018001290A2 (es)
CR (1) CR20180094A (es)
DK (1) DK3319952T3 (es)
EC (1) ECSP18010065A (es)
ES (2) ES3010714T3 (es)
HK (1) HK1255390A1 (es)
IL (1) IL256750A (es)
MX (1) MX2018000354A (es)
MY (1) MY182971A (es)
NZ (1) NZ738925A (es)
PH (1) PH12018500093A1 (es)
PT (1) PT3319952T (es)
WO (1) WO2017011210A1 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US10059683B2 (en) * 2015-07-10 2018-08-28 Noramco, Inc. Process for the production of cannabidiol and delta-9-tetrahydrocannabinol
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
US10640482B2 (en) 2017-07-21 2020-05-05 University Of South Florida Synthesis of cannabinoids
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
JP2021513553A (ja) * 2018-02-13 2021-05-27 ビートルバング ファーマ リミテッド カンナビノイド誘導体並びにそのコンジュゲート及びその使用
CN113264914A (zh) 2018-02-20 2021-08-17 麦姆德制药(佛罗里达)公司 用于治疗物质成瘾和其它障碍的遗传修饰的大麻植物和修饰的大麻素化合物
CN112292368B (zh) 2018-06-28 2024-02-02 西姆莱斯有限公司 (+)-大麻素类的合成及其治疗作用
US10736869B2 (en) 2018-07-16 2020-08-11 ECS Health Sciences, Inc. Compositions and methods related to cannabinoids, terpenoids and essential oils
CN108863768A (zh) * 2018-08-03 2018-11-23 上海华堇生物技术有限责任公司 3,5-二甲氧基苯甲酰氯的制备方法
JP2021535202A (ja) * 2018-08-20 2021-12-16 ベッソール ファルマ、エルエルシー 新規カンナビノイドおよびカンナビノイド酸ならびにそれらの誘導体
AU2019335372B2 (en) * 2018-09-05 2024-12-12 Purisys Llc Cannabidiol compositions having modified cannabinoid profiles
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
EP3653596A1 (en) * 2018-11-14 2020-05-20 Indena S.p.A. Continuous flow synthesis of cannabidiol
DE102019104563A1 (de) 2019-02-22 2020-08-27 Chiracon Gmbh Verfahren zur Herstellung von Cannabidiol
CN109970516A (zh) * 2019-03-20 2019-07-05 栾云鹏 一种工业化制备高纯度高收率的大麻酚类物质的合成方法
WO2020214574A1 (en) 2019-04-15 2020-10-22 Trustees Of Boston University One-step flow-mediated synthesis of cannabidiol (cbd) and derivatives
CN111943813B (zh) * 2019-05-17 2023-04-14 上海特化医药科技有限公司 大麻二酚类化合物的制备方法
WO2020232545A1 (en) * 2019-05-23 2020-11-26 Kare Chemical Technologies Inc. Catalytic cannabinoid processes and precursors
US20230183157A1 (en) * 2019-05-31 2023-06-15 Purisys Llc Processes for the preparation of halogenated dihydroxybenzene compounds
CA3142957A1 (en) 2019-06-11 2020-12-17 Canopy Growth Corporation Improved methods for converting cannabidiol into delta8-tetrahydrocannabinol
EP4067330B1 (en) 2019-06-11 2024-03-20 Symrise AG Cosmetic use of cannabigerol
WO2020252277A1 (en) * 2019-06-13 2020-12-17 Isomerz, Inc. Making delta 8 thc, delta 10 thc and/or cannabinol from cbd
WO2020252369A1 (en) * 2019-06-14 2020-12-17 Purisys Llc Crystalline cannabigerol
GB201910389D0 (en) 2019-07-19 2019-09-04 Gw Pharma Ltd Novel compounds, methods for their manufacture, and uses thereof
US11542243B1 (en) 2019-09-26 2023-01-03 FusionFarms, LLC Method of converting delta9-THC to delta10-THC and the purification of the delta10-THC by crystallization
CA3163788A1 (en) 2019-12-06 2021-06-10 JLABS Beauty LLC Topical compositions containing rose oil and cannabidiol and methods of making and using the same
CN115066238A (zh) * 2019-12-27 2022-09-16 海湾医学公司 大麻色原烯和相关大麻素的制备
EP4088723B1 (en) * 2020-01-08 2025-08-06 Chengdu Baiyu Pharmaceutical Co., Ltd. Cannabidiol derivative, and preparation method therefor and medical use thereof
CN113087743B (zh) * 2020-01-08 2023-04-28 成都百裕制药股份有限公司 四氢大麻酚衍生物及其制备方法和在医药上的应用
CN113087599A (zh) * 2020-01-08 2021-07-09 成都百裕制药股份有限公司 大麻二酚衍生物及其制备方法和在医药上的应用
CA3168491A1 (en) 2020-01-24 2021-07-29 Perkinelmer Health Sciences, Inc. Cannabinoid derivatives
US10981849B1 (en) * 2020-02-20 2021-04-20 Sci Pharmtech Inc. Method for preparing cannabinoids
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
US12234203B2 (en) 2020-03-12 2025-02-25 Council Of Scientific And Industrial Research An Indian Registered Body Incorporated Under The Regn. Of Soc. Act (Act Xxi Of 1860) Process for the synthesis of cannabidiol and intermediates thereof
KR20230121960A (ko) 2020-03-31 2023-08-22 피토테라퓨틱스 리미티드 테르페노페놀 화합물 및 이의 용도
AU2021276680A1 (en) 2020-05-22 2023-01-19 Ilera Derm LLC Compositions for treating acne and dermatological conditions
CN112094257B (zh) * 2020-08-19 2023-08-22 公安部禁毒情报技术中心 一种△-9四氢大麻酚的制备方法
CN112811980B (zh) * 2020-12-01 2022-03-25 山东金城金奥医药科技有限公司 一种绿色光氧化连续制备大麻二酚中间体的方法
CA3205594A1 (en) 2020-12-17 2022-06-23 Nalu Bio, Inc. Synthesis of cannabidiol and analogs thereof, and related compounds, formulations, and methods of use
CN117015401A (zh) 2020-12-21 2023-11-07 爱索思利斯制药股份有限公司 肠胃外大麻素制剂及其用途
US11242330B1 (en) * 2021-02-25 2022-02-08 Acid Neutral Alkaline Laboratory Organic catalyst and method for preparation of aromatic tricyclic pyrans
US11242328B1 (en) * 2021-02-25 2022-02-08 Acid Neutral Alkaline Laboratory Heterogeneous catalyst and method for preparation of aromatic tricyclic pyrans
US20220306598A1 (en) * 2021-03-25 2022-09-29 Precision Extraction Corporation Method for highly selective conversion of cbd to delta-8 thc
GB2628746A (en) * 2021-03-31 2024-10-02 Phytotherapeutix Ltd Terpenophenolic compounds and their use
US11352337B1 (en) * 2021-06-02 2022-06-07 Acid Neutral Alkaline Laboratory Zeolite catalyst and method for preparation of aromatic tricyclic pyrans
CN113603568A (zh) * 2021-07-19 2021-11-05 厦门朝阳生物工程有限公司 一种大麻二酚的制备方法
WO2023086447A2 (en) * 2021-11-12 2023-05-19 Pureform Global, Inc. A method for the synthesis of cannabinol
WO2024028516A1 (en) 2022-08-05 2024-02-08 Salud & Semillas, S.L. CANNABINOID SYNTHESIS STARTING OUT FROM OLIVETOL AND TERPENE IN DICHLOROMETHANE WITH FeCl3 * 6H2O AS CATALYST
AU2023322302A1 (en) 2022-08-11 2025-05-22 Cardiol Therapeutics Inc. Stable injectable cannabidiol formulations
CN117700304A (zh) * 2022-09-01 2024-03-15 卡那比生物科学有限公司 一种大麻二酚的制备方法及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH473075A (de) 1966-11-04 1969-05-31 Theodor Dr Petrzilka Verfahren zur Herstellung von in 2-Stellung substituierten Resorcinderivaten
DE4100441A1 (de) 1991-01-09 1992-07-16 Mack Chem Pharm Verfahren zur herstellung von 6,12-dihydro-6-hydroxy-cannabidiol und dessen verwendung zur herstellung von trans-delta-9-tetrahydrocannabinol
WO2001003690A1 (en) 1999-07-12 2001-01-18 Virginia Commonwealth University Novel vasodilator cannabinoid analogs
EP1482917B1 (en) * 2002-02-01 2019-05-08 GW Pharma Limited Compositions comprising cannabidiolic acid for treatment of nausea, vomiting, emesis, motion sickness or like conditions
GB2393182B (en) * 2002-09-23 2007-03-14 Gw Pharma Ltd Method of preparing cannabidiol from plant material
EP1633733B1 (en) * 2003-05-20 2011-01-26 The University of Tennessee Research Foundation Cannabinoid derivatives, methods of making, and use thereof
US7323576B2 (en) 2004-10-01 2008-01-29 Alphora Research Inc. Synthetic route to dronabinol
TWI436991B (zh) * 2004-11-22 2014-05-11 Euro Celtique Sa 用於純化反-(-)-△9-四氫大麻酚與反-(+)-△9-四氫大麻酚之方法
DE102005028937B4 (de) * 2005-06-22 2009-07-23 Bionorica Ag Verfahren zur Herstellung von Dronabinol
EP2578577A1 (en) * 2005-09-29 2013-04-10 Albany Molecular Research, Inc. Sulfonyl esters of tetrahydrocannabinol and derivatives thereof
WO2009099868A1 (en) * 2008-02-06 2009-08-13 Mallinckrodt Inc. Process for the preparation of (-) -delta 9-tetrahydrocannabinol
DE102009019322A1 (de) * 2009-04-30 2010-11-11 The Health Concept Gmbh Verfahren zur Herstellung von Synthetischen Cannabinoiden
DK3274321T3 (da) * 2015-03-23 2019-12-02 Echo Pharmaceuticals Bv Cannabidiol-isolat fra industriel hamp og anvendelse deraf i farmaceutiske og/eller kosmetiske præparater
ES2938560T3 (es) * 2015-05-28 2023-04-12 Radius Pharmaceuticals Inc Formulaciones de cannabinoides estables
US10059683B2 (en) * 2015-07-10 2018-08-28 Noramco, Inc. Process for the production of cannabidiol and delta-9-tetrahydrocannabinol

Also Published As

Publication number Publication date
PH12018500093A1 (en) 2018-07-09
WO2017011210A1 (en) 2017-01-19
ES2784881T3 (es) 2020-10-01
JP6810842B2 (ja) 2021-01-13
AU2016294264B2 (en) 2019-06-13
EP3319952B8 (en) 2020-03-11
US20170008868A1 (en) 2017-01-12
CA2992043A1 (en) 2017-01-19
EP3319952B1 (en) 2020-02-05
US20170008869A1 (en) 2017-01-12
PT3319952T (pt) 2020-04-22
US20210061781A1 (en) 2021-03-04
EP3722276B1 (en) 2025-01-08
DK3319952T3 (da) 2020-03-23
EP3722276A1 (en) 2020-10-14
BR112018000497A2 (pt) 2018-09-11
MX2018000354A (es) 2018-08-15
CL2019003154A1 (es) 2020-03-06
US20180319763A1 (en) 2018-11-08
NZ738925A (en) 2019-05-31
CA2992043C (en) 2020-04-14
ECSP18010065A (es) 2018-05-31
EP3722276C0 (en) 2025-01-08
CN108137526A (zh) 2018-06-08
US10844035B2 (en) 2020-11-24
EP3319952A1 (en) 2018-05-16
CL2018000079A1 (es) 2018-08-24
CR20180094A (es) 2018-06-14
US10059683B2 (en) 2018-08-28
JP2018522944A (ja) 2018-08-16
JP2020037596A (ja) 2020-03-12
IL256750A (en) 2018-03-29
AU2019229416A1 (en) 2019-10-03
ES3010714T3 (en) 2025-04-04
MY182971A (en) 2021-02-05
HK1255390A1 (zh) 2019-08-16
AU2016294264A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
CO2018001290A2 (es) Proceso para la producción de cannabidiol y delta-9-tetrahidrocannabinol
DOP2021000179A (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
CL2019002793A1 (es) Composición para producir tagatosa y procedimiento de producción de tagatosa usando la misma.
CO2020001927A2 (es) Método de producción de composiciones farmacéuticas que comprende el virus chikungunya inmunogénico chikv-delta5nsp3
BR112018071060A2 (pt) produção de monômeros de lignina durante a despolimerização de uma composição contendo lignocelulose
MX2014015287A (es) Derivado del ester del acido heteroarilcarboxilico.
BR112014026053A2 (pt) método de preparo de para-xileno a partir de biomassa
MX381408B (es) Mejoras en o con relación a compuestos orgánicos.
BR112016013316A8 (pt) método para a produção de furfural e uso de ácido metanossulfônico
BR112013018703A2 (pt) processo para a produção de óxido de etileno
MX2015010584A (es) Producción de cuero.
MX395589B (es) Método para preparar derivado de oxaespirociclo e intermediario del mismo.
BR112015029399A2 (pt) produção em etapa única de uma composição de polipropileno
BR112016025024A2 (pt) ?processo para preparar compostos ceto, e, uso de farnesil acetona?
MX2016000551A (es) Proceso novedoso para la preparacion de pirrolidina-dionas espiroheterociclicas.
BR112017028128A2 (pt) ?processo para a preparação de uma poliamida?
MX384794B (es) Proceso para la preparacion de 5-fluoro-1h-pirazoles a partir de hexafluoropropeno.
BR112016011899A2 (pt) Processo para preparação de 5-fluoro-1h-pirazóis
BR112017018993A2 (pt) Processo para preparar 3-cloro-2- vinilfenilassulfonatos
CO6470817A2 (es) Cristales de solvato novedosos
BR112016022437A2 (pt) Processo para preparação de (2s,5r)-6-(benziloxi)-7-oxo-1,6- diazabiciclo[3,2,1]octano-2-carboxilato de sódio
BR112016016397A2 (pt) método para preparar 1-alquil-3-difluorometil-5-fluoro-1h-pirazol-4-carbaldeídos e 1-alquil-3-difluorometil-5-fluoro-1h-pirazol-4-carboxilatos.
MX2019006959A (es) Procesos para la preparacion de compuestos de pirimidinilciclopentano.
IN2014DN07656A (es)
BR112015028751A2 (pt) processo para a preparação de derivados de 3,5-bis (fluoralquil)pirazol a partir de alfa,alfa-dihaloaminas